Form D · Biotechnology
Nexgenia Inc.
Seattle, WA · CIK 0001623317
Offering snapshot reported May 15, 2018 · SEC filing
- Reported sold
- $119K Offering amount: $250K
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 15, 2018 | Initial | $119,099 | No comparison | 14 | SEC filing |
| Apr 5, 2017 | Initial | $0 | No comparison | 1 | SEC filing |
| Aug 19, 2016 | Initial | $1,859,887 | No comparison | 15 | SEC filing |
| Jun 29, 2015 | Initial | $1,617,582 | No comparison | 9 | SEC filing |
| Oct 28, 2014 | Initial | $500,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-312465
Source: Form D, filed May 15, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Gillis | Director |
| Ron Myers | Director, Executive |
| Stewart Parker | Director |
| Martin Simonetti | Director |
| David Urdal | Director |
| Charles P. Waite | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
454 North 34 Th St. Suite Ll
Seattle, WA, 98103
Seattle, WA, 98103